文献速递甲状腺疾病

分化型甲状腺癌患者的第二原发癌:放射性碘是否起作用?

Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
PubMed 文献 · Thyroid · 2017-07-14

这项回顾性单中心研究纳入1998至2009年诊断的2031例分化型甲状腺癌患者,中位随访8.8年,比较接受与未接受放射性碘治疗者的第二原发癌风险;结果显示接受放射性碘治疗者第二原发癌风险升高,且与累积活度>200 mCi相关。

要点

  • 中位随访8.8年,接受放射性碘治疗者第二原发癌10年累积发生率为8.2%,未接受者为4.5%。
  • 第二原发癌发生率与总累积活度相关,累积活度>200 mCi时差异有统计学意义。

核心结论

  • 分化型甲状腺癌患者第二原发癌发生率虽低,但接受放射性碘治疗后风险升高,尤其累积活度>200 mCi时。
  • 鉴于分化型甲状腺癌患者生存良好,临床医生需权衡放射性碘治疗的获益与风险,尤其低危甲状腺癌患者。

研究设计与样本

  • 回顾性单中心研究,纳入1998至2009年在作者三级癌症中心诊治并随访的2031例分化型甲状腺癌患者。

主要发现

  • 患者中位年龄48岁(范围5-90岁),83%为女性,77%接受放射性碘治疗。
  • 中位随访8.8年(范围5.0-17.0年),共诊断130例第二原发癌,接受放射性碘治疗组108/1570例(6.9%),未接受组22/461例(4.8%)。
  • 最常见第二原发癌为乳腺癌(31%),其次为泌尿生殖系统癌和胃肠道癌(各18%)。
  • 第二原发癌10年累积发生率在接受放射性碘治疗组为8.2%,未接受组为4.5%。
  • 随访10年时,接受放射性碘治疗组较未接受组第二原发癌绝对风险增加为每患者年0.039(CI 0.011-0.067),需伤害人数为25.6(CI 15.0-87.2)。

关键数值与推荐

  • 接受放射性碘治疗组第二原发癌10年累积发生率为8.2%,未接受组为4.5%。
  • 接受放射性碘治疗组较未接受组第二原发癌绝对风险增加为每患者年0.039(CI 0.011-0.067)。
  • 需伤害人数为25.6(CI 15.0-87.2),即10年随访期间平均每26例接受放射性碘治疗的患者增加1例第二原发癌。
  • 校正后接受放射性碘治疗组第二原发癌相对风险为1.84(CI 1.02-3.31,p=0.026)。
  • 第二原发癌发生率与总累积活度相关,累积活度>200 mCi时差异有统计学意义。

临床怎么用

  • 临床医生需权衡放射性碘治疗的获益与风险,尤其低危甲状腺癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Well-differentiated thyroid cancer (WDTC) is the most common endocrine neoplasia, and its incidence is rising. Studies have reported an increased risk of second primary cancer (SPC) in WDTC survivors, but its relationship with radioiodine treatment (RAIT) and other risk factors remains controversial. This study evaluated whether RAIT is an independent risk factor for SPC in WDTC patients. METHODS: This was a retrospective single-center study. A total of 2031 patients with WDTC diagnosed between 1998 and 2009, treated and followed at the authors' tertiary cancer center, were included. RESULTS: The median age of patients was 48 years (range 5-90 years); 83% were women and 77% underwent RAIT. The median follow-up was 8.8 years (range 5.0-17.0 years). A total of 130 SPC were diagnosed: 108/1570 (6.9%) received RAIT (RAIT+) and 22/461 (4.8%) did not (RAIT-). The most common SPC was breast cancer (31%), followed by genitourinary and gastrointestinal cancer (18% each). The 10-year cumulative incidence of SPC was 8.2% in RAIT+ and 4.5% in RAIT-. The absolute risk increase in the RAIT+ group versus the RAIT- group at 10 years of follow-up was 0.039 [confidence interval (CI) 0.011-0.067] per patient-year. The number needed to harm (NNH) was 25.6 [CI 15.0-87.2], indicating that on average during a 10-year follow-up period, there is one additional case of SPC for every 26 patients receiving RAIT. When controlling for age, sex, and familial and personal histories of cancer, there was an 84% increase in the risk of SPC in the RAIT+ group compared to the RAIT- group (p = 0.026; relative risk = 1.84 [CI 1.02-3.31]). There was an association between SPC incidence and total cumulative activity administered, which was statistically significant >200 mCi. The incidence of SPC was higher in both the WDCT and the RAIT+ cohorts compared to the general population (standardized incidence ratios = 1.32 and 1.40, respectively). CONCLUSION: These results indicate that in spite of the low incidence of SPC in WDTC patients, the risk is increased after RAIT, particularly for activities >200 mCi. Thus, considering the excellent survival of patients with WDTC, clinicians need to weigh the risks and benefits of RAIT, especially in patients with low-risk thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Silva-Vieira M, Carrilho Vaz S, Esteves S, et al. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? Thyroid. 2017. PMID: 28614983. doi:10.1089/thy.2016.0655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。